A diagnostic centre is almost always run on throughput. The operation is organised around moving studies through, the dashboards show volume and backlog, and a good day is a day where the queue cleared. Throughput matters; a centre that cannot handle its volume safely has a real problem. But throughput is not what referrers and regulators actually use to judge a centre. They judge it on whether the report comes back when it was expected, reliably, and on whether the result can be trusted because the evidence behind it is sound. Those are the two things a centre is really judged on, and they are usually the two things it does not instrument.
This piece is a perspective on the gap between what a diagnostic centre measures and what it is judged on. The argument is opinionated. We are not arguing that throughput is unimportant, or that centres are careless about quality. We are arguing that referrer trust and regulatory standing rest specifically on turnaround reliability and on quality-assurance evidence linked to each result; that most diagnostic software instruments throughput well and these two loosely or after the fact; and that a centre optimising what it can see while running blind on what it is judged on is exposed precisely where its reputation and its regulatory position are decided. The recent consolidation of medical-equipment regulation sharpens the second of these, because equipment QA is now evidence a centre has to be able to produce, not activity it merely performs.
The audience for this analysis is operators and quality leads of UAE diagnostic and imaging centres who run a busy, well-managed throughput operation and have an uneasy sense that referrer relationships and regulatory readiness do not track their volume numbers. The useful diagnostic question is not "how many studies did we process" but "can we show, for any study, that it was reported within the expected time and that the instrument behind it was calibrated, quality-controlled, and competently operated, as one traceable chain".
What You Measure Versus What You Are Judged On
Below is a plot of the dimensions a diagnostic centre runs on, positioned by how much a centre is judged on each one against how well it typically measures it. The danger area, top-left, is where a dimension matters greatly to how the centre is judged but is poorly instrumented. The point is not that throughput is unimportant; it is that the dimensions a centre is most judged on are frequently the ones it measures least, which is the worst place for them to be. Tap any point for how much it is judged on and how well it is measured.
What a centre is judged on versus how well it measures it
Top-left is the danger area: judged on heavily, measured poorly. Tap any point.
Why Turnaround and QA Evidence Are the Real Basis of Judgement
The reason these two dimensions decide a centre's standing is the position a diagnostic centre occupies. A centre does not usually own the patient relationship; it serves referrers, who decide which centre to send work to and stake their own clinical decisions on the result. A referrer judges a centre on two things: did the report come back when I needed it, reliably enough that I can build my own workflow around it, and can I trust the result enough to act on it. The first is turnaround reliability. The second is whether the result is backed by sound, traceable quality assurance. Volume does not enter the referrer's judgement except as the capacity that makes the other two possible.
The funding and market context makes turnaround commercially sharp. Dubai's health expenditure was around AED 22.24 billion in 2023, roughly 61 per cent privately financed, across a market of 5,372 licensed facilities in 2024. In a competitive, referral-driven, privately financed market, referrers have alternatives, and reliable turnaround is one of the few things that durably differentiates a centre and holds the referral relationship. A centre that can quote an average turnaround but cannot guarantee it by modality or see a breach before the referrer does is competing on the dimension it manages worst.
The QA dimension has just been sharpened by regulation. The consolidation of medical-equipment regulation under the Emirates Drug Establishment in late 2025 raises the expectation that equipment quality assurance is producible evidence, traceable to the result it stands behind, not merely activity recorded in a separate log. For a diagnostic centre this is direct: the calibration and quality control of the instrument is part of whether a specific result can be trusted, and a regulator focused on equipment will expect the chain from study to instrument state to be demonstrable. The dimension a centre is most judged on for trust is now also the one regulation most expects it to be able to prove, and it is typically the least instrumented.
The shift in one observation
A diagnostic centre measures throughput because throughput is what its operation is organised around and what is easiest to see. It is judged, by the referrers who feed it and the regulators who oversee it, on whether reports come back reliably and whether results are backed by traceable QA evidence. Optimising the visible dimension while running blind on the two that decide reputation and regulatory standing is the structural exposure, and it stays invisible until a referrer drifts away or an inspection asks for the chain.
Where the Throughput Model Breaks
The throughput-instrumented model breaks in four predictable places against the dimensions a centre is actually judged on.
Turnaround known on average, not managed
An average turnaround hides the breaches that lose referrers. The studies that damage a relationship are the late outliers in a specific modality, and a centre that tracks the mean cannot see or manage the tail. The number that protects the referral relationship is reliability by modality, not an average across everything.
Breaches discovered by the referrer
When turnaround is reconciled after the fact, the referrer learns about a late report before the centre does. The centre is then explaining a failure it did not see coming, which erodes trust faster than the delay itself. Being told by your customer that you missed is worse than the miss.
QA activity not linked to the result
Quality control that happens but is not linked to the individual study cannot be produced as evidence for that result. The centre did the QA and still cannot prove the result is backed by it, which under consolidated equipment regulation is the gap that matters most and the one a throughput system does not close.
Instrument state not traceable to the study
If the calibration and maintenance state of the instrument at the time of a study cannot be tied to that study, a question about a result cannot be answered by following one chain. The evidence exists in pieces, in logs and spreadsheets, and assembling it under inspection pressure is exactly when it fails.
The Numbers
Two Ways to Run a Diagnostic Centre
The difference between centres that hold referrers and pass inspection cleanly and those that do not is whether they instrument what they are judged on or only what they run on.
| Dimension | Throughput-instrumented | Judged-on-instrumented |
|---|---|---|
| Turnaround | An average, reconciled after the fact. | A managed commitment by modality, breaches surfaced early. |
| Breach awareness | The referrer finds out first. | The centre sees the breach before the referrer does. |
| QA | Activity in a separate log. | Evidence linked to the individual result. |
| Instrument state | In pieces, assembled under pressure. | Traceable from study to instrument as one chain. |
| Throughput | The thing measured best and judged on least. | Still measured, as the capacity that enables the rest. |
A diagnostic centre is not judged on how many studies it cleared. It is judged on whether the report came back when it was promised and whether the result can be trusted because the evidence behind it holds. A centre that instruments throughput and not those two is measuring the dimension it is judged on least and running blind on the two that decide its reputation and its regulatory standing.
What a Judged-On-Instrumented Centre Looks Like
The pattern in centres that hold referrers and meet a consolidated regulator cleanly is recognisable. Turnaround is a managed commitment by modality, not an average, with breaches surfaced inside the centre before the referrer experiences them. Quality control and calibration are linked to the individual result, so the evidence that a specific study is trustworthy can be produced as one chain rather than assembled from separate logs. The instrument state at the time of each study is traceable to that study, so a result-integrity question is answered by following the chain, not by reconstruction. Throughput is still measured, because capacity is real, but it is understood as the thing that enables the two dimensions the centre is judged on rather than as the goal itself.
This does not necessarily mean replacing the information or equipment systems already in place. In many centres the turnaround management and the QA-to-result linkage can be built around the existing systems, provided they can hold turnaround as a per-modality commitment and link QA and instrument state to the study. Replacement becomes the better option mainly where the existing systems structurally cannot manage turnaround as a commitment or cannot tie QA evidence to the individual result. Which applies is specific to the systems in place and the modality mix, and is established in scoping before any build commitment.
How This Sits Alongside the Centre's Own Responsibilities
The configuration keeps a clear separation. The diagnostic centre delivers and reports the studies, employs and licenses its clinicians and technologists, performs and signs off its own quality assurance, holds the relationship with the regulator, and is responsible for its own clinical and regulatory obligations. The software is the instrumentation: turnaround as a managed commitment, and QA and instrument state linked to each result as producible evidence.
This is the role BY BANKS is positioned for. We are an independent software engineering company based in the UAE. We design and build software and hand it over to the centre that runs it. We do not perform diagnostics, interpret studies, conduct or certify quality assurance, or make clinical or regulatory determinations, we are not a regulated healthcare entity, and we are not affiliated with the Emirates Drug Establishment or any authority. The centre owns the diagnostics, the QA, the clinical and regulatory determinations, and its own compliance; we build the system that makes turnaround manageable and QA producible as evidence. The accountable party leads and owns the obligations; we build to their direction.
Where This Analysis Is Useful
The conversations where this perspective is most useful tend to be at three moments: a centre with strong throughput numbers that is quietly losing referrers and cannot say why; a quality lead who knows the QA is being done but cannot produce it as evidence linked to a specific result; or an operator absorbing the consolidated equipment regulation and realising QA recorded in logs is not the same as QA traceable to a study. The honest answer is usually the same: the centre is judged on turnaround reliability and QA evidence, those are the two it instruments least, and the exposure stays invisible until a referrer drifts or an inspection asks for the chain.
For broader related work, see our perspective on what the 2025 shift of equipment regulation to the EDE means and our perspective on why claims in Dubai are decided at the point of care. The applied work sits across our diagnostic centre software and medical equipment tracking software capabilities, within the broader healthcare software practice and our operational platforms work. Get in touch if a 45-minute conversation about a specific centre would be useful.
Frequently Asked Questions
No. We are an independent software engineering company based in the UAE. We design and build software and hand it over to the centre that runs it. We do not perform diagnostics, interpret studies, conduct or certify quality assurance, or make clinical or regulatory determinations, and we are not a regulated healthcare entity. On any engagement, the centre owns the diagnostics, the QA, and its own compliance. We build the system that makes turnaround manageable and QA producible as evidence; the centre performs and owns the clinical and quality work.
No. Throughput is real capacity, and a centre that cannot handle its volume safely has a genuine problem. The argument is about the basis of judgement: referrers and regulators decide on turnaround reliability and QA evidence, not on raw volume, and throughput is best understood as the capacity that enables those two rather than as the goal. It should still be measured; it just is not the dimension a centre is judged on.
Performing QA and being able to produce it as evidence for a specific result are different things. QA recorded in a separate log proves the activity happened; it does not, on its own, demonstrate that this study was backed by it without reconstruction. Under consolidated equipment regulation the expectation moves toward traceable evidence linked to the result. The QA you already do is the foundation; linking it to the study is what turns it into the evidence you are judged on.
Often not. In many centres turnaround management and QA-to-result linkage can be built around the systems already in place, provided they can hold turnaround as a per-modality commitment and link QA and instrument state to the study. Replacement becomes the better option mainly where the existing systems structurally cannot manage turnaround as a commitment or tie QA evidence to the individual result. Which applies is specific to the systems in place and is established in scoping before any build commitment.
It is sequenced and does not require pausing the centre. The usual starting point is turnaround as a managed commitment for the modalities and referrers where the relationship risk is greatest, so breaches are seen internally before referrers experience them. QA-to-result linkage and instrument-state traceability follow, prioritised by the studies and equipment classes where the regulatory and trust consequence is largest. The order is driven by where the centre is most judged and least instrumented, which scoping establishes for the specific centre.
A diagnostic centre is widely run and measured on throughput and is in fact judged, by the referrers who feed it and the regulators who oversee it, on whether reports come back reliably and whether results are backed by traceable QA evidence. Those two dimensions are usually the ones a centre instruments least, and the consolidation of equipment regulation has sharpened the second of them. The centres that hold referrers and meet a consolidated regulator cleanly are the ones that instrumented turnaround as a commitment and QA as evidence linked to each result, while still measuring throughput as the capacity that enables both. The build is software work; the diagnostics, the quality assurance, and the clinical and regulatory determinations remain entirely the centre's, and the system simply makes the two dimensions it is judged on visible and producible rather than assumed.
References to the Emirates Drug Establishment, the 2025 consolidation of medical-equipment regulation, and the Dubai diagnostic market are descriptive of publicly known frameworks and information. The funding and facility figures cited (Dubai health expenditure of approximately AED 22.24 billion in 2023, around 61% privately financed, and 5,372 licensed Dubai health facilities in 2024) are drawn from public sources listed on our Sources and Data page; the quadrant positions and other patterns in this article are an observational model rather than measured data, and represent no specific centre or system. BY BANKS is an independent software engineering company; we do not perform diagnostics, interpret studies, conduct or certify quality assurance, or make clinical or regulatory determinations, and we are not a regulated healthcare entity or affiliated with any authority. On any healthcare engagement, the centre owns the diagnostics, the quality assurance, the clinical and regulatory determinations, and responsibility for its own compliance. This article is not regulatory, clinical, or quality advice; operators should obtain qualified advice for their specific obligations. Public sources used in this piece are listed on our Sources and Data page.
Ready to Build Something?
If this resonated, let's talk about how we can apply these ideas to your business.
Start a Conversation